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Background: Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system
(CNS), which is characterized by the presence of pathogenic serum autoantibodies against aquaporin 4 (AQP4) in
the vast majority of patients. The contribution of T cells to the formation of astrocyte destructive lesions is currently
unclear. However, active human NMO lesions contain CD4+ T-lymphocytes expressing the activation marker Ox40,
and the expression is more profound compared to that seen in MS lesions of comparable activity. Therefore, we
analyzed the role of T-cell activation within the CNS in the initiation of NMO lesions in an experimental model of
co-transfer of different encephalitogenic T-cells and human AQP4 antibody containing NMO immunoglobulin
(NMO IgG). We further studied the expression of the T-cell activation marker Ox40 in NMO and multiple sclerosis
lesions in different stages of activity.
Results: All encephalitogenic T-cell lines used in our experiments induced brain inflammation with a comparable
extent of blood brain barrier damage, allowing human NMO IgG to penetrate into the brain and spinal cord tissue.
However, astrocyte destructive NMO lesions were only seen with T-cells, which showed signs of activation in the
lesions. T-cell activation was reflected by the expression of the activation marker Ox40 and pronounced production
of γ-IFN, which was able to increase the production of complement proteins and of the Fc gamma III receptor (Fcgr3)
and decreased production of complement inhibitory protein Factor H in microglia.
Conclusions: Our data indicate that local activation of T-cells provide an inflammatory environment in the CNS,
which allows AQP4 auto-antibodies to induce astrocyte destructive NMO-like lesions.
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Neuromyelitis optica (NMO) is an astrocytopathic disease
of the central nervous system (CNS) characterized by
optic neuritis, transverse myelitis, and – in the vast
majority of patients – by the presence of specific auto-
antibodies, the so-called NMO-IgGs [1]. These antibodies
are directed against aquaporin 4 (AQP4), a water channel
particularly enriched on astrocytic processes at the glia
limitans [2,3], and they are pathogenic. They can bind
to AQP4 on the surface of astrocytes, fix complement,
and initiate complement-mediated destruction of these
cells [4,5]. Based on earlier findings in NMO models it* Correspondence: monika.bradl@meduniwien.ac.at
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stated.became clear that the presence of serum NMO-IgG is
not sufficient to initiate astrocyte-destructive lesions [5],
similar to the situation in NMO patients, who can be
NMO-IgG seropositive for many years without showing
clinical evidence of NMO [6]. Interestingly, even the
presence of NMO-IgG and complement components in
the CNS parenchyma is insufficient to promote the forma-
tion of large experimental NMO lesions, as seen when
NMO-IgG and complement is injected directly into the
striatum of mice with low numbers or abolished effector
functions of circulating neutrophils [7], or when NMO-
IgG and complement gain access to the brain through a
blood–brain barrier that is developmentally leaky [5,8]
or was rendered leaky due to the action of toxins [8] or
to the intra-cerebral injection of cytokines [9]. All thesed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Characteristics of the NMO and MS tissues used
Disease Activity Region
case-block
NMO 1-1 LA Cerebellum, medulla oblongata
NMO 1-2 EA Spinal cord
NMO 1-3 LA Spinal cord
NMO 1-4 EA Spinal cord
NMO 1-5 LA Mesencephalon
NMO 1-6A LA Periventricular (4th ventricle)
NMO 1-10A LA Temporal lobe
NMO 2-49 Acute, EA Optic nerve
NMO 3-2 Chronic, IA Spinal cord
NMO 4-49 Subacute/chronic LA-IA Spinal cord
NMO 5-2 EA, LA Medulla oblongata
NMO 6-2 LA Spinal cord
NMO 6-4 IA Medulla oblongata
AMS 1-1A EA, LA, IA Spinal cord
AMS 1-10D EA, LA, IA Temporal lobe
SPMS 1-12 SEL, IA Optic nerve
SPMS 1-10 SEL IA Medulla
SPMS 2-19 SEL IA Spinal cord
SPMS 2-20 SEL, IA Spinal cord
SPMS 2-21A SEL, IA Spinal cord
AMS 6-15 IA Spinal cord
SPMS 3-31 SEL, IA Medulla oblongata
AMS 2-6 EA Brain
RRMS 1 EA, LA Brain
AMS 3-5 EA, LA Brain
AMS 4-2 EA, LA Brain
AMS 5-97 EA, LA Brain
Active lesions were identified and staged based on their dense infiltration by
macrophages/activated microglia, and, in the case of NMO, by the presence of
large numbers of neutrophilic granulocytes. Macrophages contained either
early myelin degradation products (i.e. they were MOG+; early active lesions
(EA)) or late myelin degradation products (i.e. they were PLP+; late active
lesions (LA)). Inactive lesions (IA) had sharp lesion borders without
macrophage infiltration of microglia activation, and slowly expanding lesions
(SEL) were classified according to their inactive center, surrounded by a rim of
activated microglia with some macrophages with myelin degradation products
at the lesion margin.
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mechanisms are needed to initiate/promote astrocyte-
destructive lesions. Further studies revealed that these
mechanisms are triggered by CNS inflammation. In
NMO patients, active NMO lesions are characterized
by complement deposition on and subsequent destruction
of astrocytes, and have a pronounced inflammatory
component as evidenced by the presence of T cells,
many neutrophils, macrophages/activated microglia cells
and some eosinophils [10,11]. In experimental NMO,
lesions were induced by myelin basic protein (MBP)-
specific T cells in NMO-IgG seropositive Lewis rats, and
faithfully reproduced essential features of active lesions
in NMO patients [4,5]. Since the antigen recognition of T
cells found in NMO lesions is still unknown, the findings
in experimental NMO raise important questions: Are
all CNS antigen-specific T cells similarly able to initiate
astrocyte-destructive lesions in NMO-IgG seropositive
hosts? And if not, what are the requirements for T cells to
do so? These questions were answered in the current study.
Methods
NMO IgG preparation
The IgG preparation of the NMO patient J0 used has
been extensively characterized before [5], and is termed
NMO-IgG throughout this article. Its use was approved
by the Ethics Committee of Tohoku University School
of Medicine (No. 2007–327).
Human tissue samples
Autopsy CNS tissue of 6 NMO and 10 MS patients
(Table 1) from paraffin blocks and sections archived
in the Center of Brain Research, Medical University
Vienna, Austria or in Tohoku Medical University was
used. The study was approved by the Ethical Committee
of the Medical University of Vienna (EK. No. 535/2004
and 087/01/2012).
Animals
8 week-old Lewis rats from Charles River Wiga (Sulzfeld,
Germany) were used. They were housed in the Decentral
Facilities of the Institute for Biomedical Research (Medical
University Vienna) under standardized conditions. The
experiments were approved by the Ethics Committee of
the Medical University Vienna and performed with the
license of the Austrian Ministery for Science and Research.
Induction of experimental autoimmune encephalomyelitis
(EAE) and tissue preparation
T cell lines against myelin basic protein (MBP, from
guinea pig, Sigma), myelin oligodendrocyte glycoprotein
(MOG, recombinant N-terminal peptide 1–125, rat, own
production) and the astrocytic Ca2+ binding protein S100β
(bovine, Sigma) were intraperitoneally injected to induceEAE. These T cell lines have been established and expanded
under conditions favoring TH1 cells, but not TH17 cells.
Weight loss as earliest clinical sign of EAE started 4 days
after the transfer. At this time point the animals received
an intra-peritoneal injection with 1 ml phosphate buffered
saline (PBS) containing either 10 mg NMO-IgG [5] or
10 mg normal human IgG (SubcuviaR) [5]. 24 hours
later, the animals were sacrificed with CO2 and perfused
with 4% phosphate buffered paraformaldehyde (PFA).
Brains and spinal cords were dissected, immersed for
another 18 hours in PFA, and embedded in paraffin.
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cent protein (GFP), EAE induction with these cells, their
re-isolation from CNS lesions and their characterization
by flow cytometry followed established procedures [12,13].
Determination of IFN-γ production by polymerase
chain reaction
RNA was purified using the RNeasy kit with QIAshredders
(Qiagen), converted to cDNA, and subjected to real-time
polymerase chain reactions (RT-PCR) using the Power
SYBR® Green PCR Master Mix in a StepOnePlus RT-PCR
system (both from Applied Biosystems) according to the
manufacturers’ instructions. A 25 μl reaction mixture was
used for each sample, containing cDNA and primer sets
(200 nM) for IFN-γ (forward: 5′-ATTCATGAGCATCG
CCAAGTTC-3′, reverse:
5′-TGACAGCTGGTGAATCACTCTGAT-3′; available
at Real-Time Primer and Probe Database, RTPrimerDB
ID:3773; https://medgen.ugent.be/rtprimerdb/; [14]) or
beta actin (Actb; forward: 5′-AGGCCAACCGTGAAA
AGATG-3′; reverse: 5′-ACCAGAGGCATACAGGGA
CAA-3′; [15]). The initial 10-min denaturation step at
95°C was followed by 40 cycles of denaturation (95°C,
15 s) and annealing/extension (60°C, 1 min). The absence
of non-specific amplification was determined by melt
curve analysis. All reactions were run in duplicates.
Immunohistochemistry
All tissue blocks were cut and stained as described [5],
using the following antibodies: W3/13 (T-cells and
granulocytes; mouse monoclonal; Serotec, UK); ED1
(macrophages, microglia; mouse monoclonal; Serotec,
UK); commercial anti-AQP4 (rabbit polyclonal; Sigma,
Germany); anti-GFAP (rabbit polyclonal; Dako, Denmark,
or mouse monoclonal; Neomarkers, USA); anti-human im-
munoglobulin (biotinylated donkey; polyclonal; Amersham,
UK) and anti-complement C9 (rabbit polyclonal [16]).
Immunohistochemistry was completed by using appropriate
biotinylated secondary antibodies (sheep anti-mouse,
donkey anti-rabbit, donkey anti-sheep/goat; all from GE
Healthcare/Amersham) and subsequent incubation of the
sections with peroxidase-labelled avidin (Sigma, Germany).
For double immunostainings of OX40 and Tcell markers,
sections were incubated with anti-OX40 (1:30, Pharmingen)
overnight at 4°C, washed, further reacted with biotinylated
donkey-anti-rabbit antibodies (1:500 Jackson ImmunoRe-
search, West Grove PA, USA) for 1 hour at RT, incubated
with avidin-alkaline phosphatase (Sigma, Germany) and
developed with Fast Blue (FB, Sigma, Germany) substrate.
To retrieve CD4 or CD8 epitopes and inactivate the
binding properties of the first round of antibodies (anti-
Ox40 and biotinylated anti-rabbit), sections were steamed
in a food steaming device in TRIS buffer containing EDTA
(10 mM, pH= 9.0) for 90 minutes. Then, anti-CD4 (Ab8,Neomarkers, 1:100 plus 1 F6, Acris, 1:500) or anti-CD8
antibodies (SP16, Neomarkers, 1:250) were applied over-
night at 4°C, followed by washing and incubation with
biotinylated donkey-anti-rabbit antibodies and tyramide
enhancement [17]. Finally, avidin-peroxidase (Sigma) was
applied and sections were developed with aminoethyl
carbazole (AEC, Sigma).
For double immunostainings of proliferating cell nuclear
antigen (PCNA) and OX40, sections were steamed in
citrate buffer for 30 minutes. Then, mouse anti-PCNA
(clone PC10, Dako, 1:50000) was applied overnight at 4°C.
The sections were washed, incubated with biotinylated
anti-mouse antibodies (Jackson ImmunoResearch, West
Grove PA, USA, 1:500) for 1 hour, washed again, incubated
with avidin-alkaline phosphatase (Sigma, Germany) and
developed with Fast Blue (FB, Sigma, Germany) substrate.
Afterwards, the sections were steamed for 45 minutes
with TRIS buffer containing EDTA (10 mM, pH = 9.0)
to destroy free binding sites of the biotinylated anti-mouse
antibodies used before, incubated with anti-OX40 (1:1000)
overnight at 4°C, washed, further reacted with biotinylated
anti-mouse antibodies (1:500) for 1 hour at RT and tyra-
mide enhancement [17]. Finally, avidin-peroxidase (Sigma)
was applied and sections were developed with aminoethyl
carbazole (AEC, Sigma).
For fluorescent double labeling, Ox40 (mouse antibody)
and anti-CD3 (rabbit antibody) were applied simultan-
eously at 4°C overnight. After washing with PBS, goat-
anti-rabbit Cy3 (Jackson ImmunoResearch, West Grove,
Philadelphia; 1:200) and biotinylated anti-mouse (Amersham
Pharmacia Biotech; 1:200) antibodies were applied simul-
taneously for 1 hour at RT. The staining was finished by
application of streptavidin-Cy2 (Jackson ImmunoRe-
search; 1:75) for 1 hour at RT. Fluorescent preparations
were examined using a confocal laser scan microscope
(Leica SP5, Leica Mannheim, Germany). Scanning for Cy2
(488 nm) und Cy3 (543 nm) was performed sequentially
to rule out fluorescence bleed-through.
Microglia cultures and gene expression profiling upon
IFN-γ-treatment
Microglia cultures were essentially produced as described
[18] and had a purity of ~99%. They were treated with
100 ng/ml IFN-γ for 48 hrs. Then, total RNA was isolated,
the mRNA transcribed to cDNA and sent to ImaGenes
(Berlin, Germany) for gene expression studies, using 4x44
K Multiplex whole rat genome microarrays (Agilent
G4131F). The raw data were subjected to quantile nor-
malizations prior to comparison between groups and
calculation of fold changes in expression.
Statistical evaluation
Statistical evaluations were performed using the PASW
statistics 18 software system (SPSS Inc., Chicago, USA).
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Active NMO lesions contain activated CD4+ T cells
CD4+ T cells expressing the activation markers OX40
and PCNA are found in NMO lesions, independent of
their location within the neuraxis (Figures 1 and 2). The
numbers of Ox40+ T cells were significantly higher in early
active than in inactive NMO lesions (Figure 3), and in
early active NMO compared to early active MS. Moreover,
also the total numbers of T cells in early active NMO
lesions were significantly higher than in inactive NMO
lesions, while there was no statistically significant difference
in T cell numbers between early active, inactive, or slowly
expanding MS lesions (Figure 3). What is the relevance
of this finding for the formation of astrocyte-destructive
lesions in NMO?
T cells with different CNS antigen-specificities are
differentially activated within the CNS
To address this question, we studied the extent of T cell
activation in EAE provoked by T cells with different
CNS antigen-specificities. T cells specific for MBP, S100β,
and MOG were labeled with GFP as described [12], and
used for the induction of EAE. At the peak of EAE, we
re-isolated these cells from the CNS, and studied their
surface expression of the CD3-T cell receptor (TCR)
complex, the IL-2R, and the Ox40 antigen as surrogate
markers of T cell activation [12]. We found that MBP-
specific T cells were strongly activated in the CNS, asFigure 1 Ox40 expression by T cells in NMO lesions. (A-C) Confocal m
antibodies against Ox40 (A, red) and CD3 (B, green) (overlay C, yellow). The
Further stainings of NMO lesions with antibodies against Ox40 (brown) and
expression on CD8+ T cells, both in perivascular lesions (D) and in the pare
products are expressed by CD4+ T cells (purple), as seen in this perivasculaindicated by a down-modulation of the TCR, and by
increased levels of IL-2R and the Ox40 antigen. S100β-
specific T cells had an intermediate activation status, as
revealed by unchanged expression levels of the TCR, by
marginally increased levels of IL-2R and moderately
increased levels of the Ox40 antigen. MOG-specific T
cells, finally, did not show any increase in IL-2R and
Ox40 antigen expression, and were hence not significantly
activated within the CNS (Figure 4, Additional file 1:
Figure S1). This is in marked contrast to the situation
in vitro, where all these cells can be readily activated and
expanded in response to their cognate antigen in the con-
text of rat MHC class II products ([12], own observation).
T cells which are differently activated in the CNS differ in
their ability to induce astrocyte-destructive lesions in
NMO-IgG seropositive rats
We then used T cells which are differently activated in
the CNS, i.e. T cells specific for MBP-, S100β-, and
MOG to induce EAE prior to the transfer of NMO-IgG.
We found that all EAE models had similar NMO-IgG
titres in the serum (between 1:320 and 1:1280; titres
evenly distributed between the different groups),, that all
T cells entered the CNS (Figure 5) and opened the
blood–brain barrier for the entry of immunoglobulins
(Figure 6). However, there were profound differences in
the extent of astrocyte destruction. MBP-specific T cells
induced the highest numbers of and the largest lesionsicroscopy of a perivascular early active NMO lesion stained with
Ox40 antigen is expressed by a subset of T cells (white arrow). (D-F):
CD8 (blue) (D-E) or CD4 (blue, F) reveals a complete absence of Ox40
nchyma at the edge of a demyelinating lesion (E). In contrast, Ox40
r lesion. Bars: 25 μm (A-C) and 50 μm (D-F).
Figure 2 Differences in Ox40 expression by CD4+ T cells between NMO and MS lesions. Inflammatory lesions derived from spinal cords of
NMO (A,B,C) and MS patients (D,E,F), and from brains of NMO (G,H,I) and MS patients (J,K,L) were reacted with antibodies specific for AQP4 (brown
reaction product; counterstaining with hematoxylin reveals nuclei in blue; A,G), CD3 (brown reaction product; B,E,H,K), Ox40 (brown reaction product;
C,F,I,L) or were stained with Kluever-Barrera to reveal myelin (blue; D,J). The spinal cord lesions shown are early active, as revealed by the large number
of granulocytes in NMO (inlay in A) and by the presence of myelin degradation products in macrophages in MS (D). The brain lesions shown are late
active in NMO, and early active, as revealed by macrophages containing myelin degradation products in MS (inlay in J). The inlays in I and L show
Ox40+ T cells. In early active NMO lesions, 18% of all perivascular and 24% of all parenchymal OX40+ cells also express the proliferating cell nuclear
antigen PCNA (M-O; PCNA visualized by the dark blue, Ox 40 by the brown reaction product).
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facilitated the formation of astrocyte-destructive lesions,
but the number of these lesions was significantly lower
than the one found after transfer of MBP-specific T cells.
In addition, there was a trend towards smaller lesions
with AQP4-loss (Figure 7). Finally, MOG-specific T cells
also infiltrated the CNS parenchyma, but did not induce
astrocyte-destructive lesions (Figure 7). What are the
differences between these T cells?
Differences in T cell activation within the CNS translate into
differences in the recruitment of macrophages/activated
microglial cells
Differences in T cell activation have consequences for the
expression of chemokines responsible for the recruitmentof macrophages/activated microglial cells [12]. We there-
fore studied the numbers of these cells in the inflamed
spinal cords of NMO-IgG seropositive hosts. We found
that MBP-specific T cells recruited the highest numbers
of activated microglial cells/macrophages, S100β-specific
T cells intermediate numbers, and MOG-specific T cells the
lowest numbers (medians 1464, 167, and 39 ED1+ cells/mm2
of spinal cord cross sections, respectively; Figure 5).
Differences in T cell activation within the CNS translate into
differences in IFN-γ production, which affects the microglial
expression of complement factors/inhibitors and of Fcgr3
Since EAE and NMO/EAE in Lewis rats are TH1-driven
diseases with IFN-γ as lead cytokine, we next deter-
mined the IFN-γ expression of the re-isolated MBP-, S100β-,
Figure 3 Numbers of Ox40+ and CD3+ T cells in NMO and MS lesions at different lesion stages. The number of Ox40 (A,B) and CD3
(C,D) positive T cells of 7 NMO (A,C) and 9 MS (B,D) cases was determined by evaluating regions of interest in NMO (ROI n = 144) and MS
(ROI n = 112) (each region = 390.000 μm2) in spinal cord and brain lesions/inflamed parenchyma. Asterisks indicate statistically significant (p < 0,05;
Mann Whitney U test with asymptotic significance (2 tailed)) differences between early active (n = 35) and inactive (n = 29) NMO lesions in the
numbers of Ox40+ T cells (A) and CD3+ T cells (C). The differences between early active (n = 51) and inactive (n = 34) MS lesions in the numbers
of Ox40+ T cells (B) and CD3+ T cells (D) were not significant (p = 0,57 and p = 0,107, respectively). Please note that the differences in numbers of
Ox40+ T cells and CD3+ T cells between early active NMO (n = 35) and early active MS (n = 51) is also highly significant (p < 0,0001 and
p = 0,000318, respectively).
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MBP-specific T cells had significantly higher relative IFN-γ
mRNA expression levels than their S100β- or MOG-
specific counterparts (Figure 8). We next stimulated
microglia with IFN-γ or vehicle (control) in vitro, and
studied the IFN-γ induced changes in the expression of
transcripts encoding complement proteins and Fcgr3. We
observed a profound upregulation of complement compo-
nent 1, r subcomponent (C1r), complement component 1,
q subcomponent, C chain (C1qc), complement component2 (C2), complement component 3 (C3), complement com-
ponent 6 (C6), and complement factor B (Cfb), coinciding
with the downregulation of the inhibitory complement
factor H (CfH) and of “similar to complement factor
H-related protein” (sim. to CfH). We also found a pro-
found upregulation of Fcgr3 (Figure 8).
Discussion
Although T cells are regularly found in NMO lesions,
our knowledge about these cells is rather limited. For
Figure 4 T cells with different CNS antigen-specificity are activated to different extent in the CNS. Analysis of surface markers by flow
cytometry. Histograms are shown. GFP-labeled MBP-, S100β-, and MOG-specific T cells isolated from the spleen (blue) or spinal cord (green) of
recipient rats were isolated at the acute phase of clinical symptoms and analyzed for the expression of T cell receptors (TCR), interleukin-2 receptors
(IL-2R) or the Ox40 antigen, using specific antibodies for these molecules and an isotype control (IgG). MBP-specific T cells were strongly activated, as
evidenced by a down-regulation of TCR, and an up-regulation of IL-2R and the Ox40 antigen. S100β-specific T cells showed an intermediated degree
of activation (i.e. no downregulation of TCR, weak up-regulation of IL-2R and Ox40 antigen), and MOG-specific T cells were not noticeably activated, as
revealed by the lack of upregulation of IL-2R and the Ox40 antigen).
Pohl et al. Acta Neuropathologica Communications 2013, 1:85 Page 7 of 13
http://www.actaneurocomms.org/content/1/1/85example, we do not know yet whether these cells
recognize AQP4 [21] or other CNS antigens, and whether
these cells initiated the lesions or were non-specifically
recruited to these sites. However, we learned from
experimental models of MS or NMO that only migra-
tion-competent CNS antigen-specific T cells can cross
through the brain capillary endothelium, open the
blood–brain barrier for the subsequent entry of additional
inflammatory mediators, and initiate inflammatory CNS
lesions. This immigration phase is similar in all CNS
antigen-specific T cells, irrespective of their pathogenicity
[12]. However, only highly pathogenic T cells are subse-
quently activated within the CNS [12]. We show here that
the extent of T cell activation within the tissue is a critical
parameter for the formation of astrocyte-destructive
lesions in NMO-IgG seropositive rats, and we provideevidence for the presence of activated CD4+ T cells in
CNS lesions of NMO patients, suggesting that these
lesions have been initiated by pathogenic T cells recog-
nizing antigens in the CNS.
Full activation of T cells in the CNS – as exemplified
in our study by MBP-specific T cells - translates into
the profound up-regulation of Ox40, increased levels of
IL-2R, down-modulation of TCR, and robust production
of IFN-γ [12,22,23]. Engagement of Ox40 with its ligand
supports the survival of T cells and augments antigen-
driven TCR-signaling in these cells [24]. Interactions of
Ox40 with Ox40L on the surface of antigen presenting
cells enhances their production of pro-inflammatory cyto-
kines like IL-1 beta or IL-6 and their surface expression
of co-stimulatory molecules [25,26]. Interestingly, IFN-γ
triggers the expression of Ox40L in microglia [27] and
Figure 5 (See legend on next page.)
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Figure 5 T cells infiltration of the spinal cord following the initiation of NMO-like lesions in NMO-IgG seropositive animals by T cells
with different CNS antigen-specificities. (A-F) T cells specific for MBP (A,B), S100β (C,D) and MOG (E,F) were used to induce CNS
inflammation, followed by transfer of NMO-IgG 4 days later. The animals were sacrificed 5 days after T cell transfer. For histological evaluation,
their spinal cords were reacted with anti-CD3 antibodies (brown reaction product) and counterstained with hematoxylin to reveal nuclei (blue).
bars = 500 μm (A,C,E) and 100 μm (B,D,F). (G) The average number of T cells per mm2 of lesions was determined by evaluating 5 representative
spinal cord cross sections (1 cervical, 2 thoracal, 2 lumbar cross sections) per animal, using 5 animals (MBP- and MOG-specific T cells) or 4 animals
(S100β-specific T cells) per group. Asterisks indicate statistically significant (p < 0,05) differences between individual CNS antigen specificities of the
T cells used to induce CNS inflammation (Kruskal-Wallis followed by Mann–Whitney U test and Bonferroni-Holm correction; p = 0,0476 for MBP/
S100β and S100β/MOG, p = 0.858 for MBP/MOG). (H) Numbers of ED1+ cells (activated microglia/macrophages) in spinal cord cross sections. The
cell numbers were determined by evaluating one complete spinal cord cross section per animal, using 5 animals (MBP- and MOG-specific T cells) or 4
animals (S100β-specific T cells) per group. Asterisks indicate statistically significant (p < 0,05) differences between individual CNS antigen specificities of
the T cells used to induce CNS inflammation (Kruskal-Wallis followed by Mann–Whitney U test and Bonferroni-Holm correction; p = 0,048 for MBP/
S100β, p = 0,024 for MBP/MOG, and p = 0,189 for S100β/MOG).
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up-regulation of complement factors and the down-
regulation of complement inhibitors which could favor
the antibody and complement mediated destruction of
astrocytes in experimental NMO lesions. IFN-γ also induces
the upregulation of Fcgr3, which plays an important
role in antibody-dependent cell-mediated cytotoxicity
(ADCC). The binding of the antibody Fc region to Fc
gamma receptors on activated microglia/macrophagesFigure 6 Entry of human immunglobulins to lesions provoked
by different CNS antigen-specific T cells in NMO-IgG seropositive
animals. (A-F) T cells specific for MBP (A,B), S100β (C,D) and MOG
(E,F) were used to induce CNS inflammation, followed by transfer of
NMO-IgG 4 days after T cell transfer. The animals were sacrificed 5
days after T cell transfer. For histological evaluation, their spinal cords
were reacted with anti-human IgG (brown reaction product) and
counterstained with hematoxylin to reveal nuclei (blue). Overviews
(A,C,E) and details (B,D,F) of representative spinal cord sections are
shown. Bars = 100 μm.promotes their accumulation and plays an important
role in NMO pathology, as evidenced by a reduction of
tissue damage in NMO models involving mice lacking
Fcgr3, mice treated with Fcgr blockers, or mice containing
mutated NMO-IgG without ADCC function [28].
Fully activated T cells also produce CCL2 and CCL3
transcripts [12] which may further attract large numbers
of macrophages/activated microglia to the lesions.
The intermediate activation of T cells – as exemplified
by S100β-specific T cells – recruits much less macro-
phages/activated microglial cells, which is in line with
lower expression levels of CCL2 and CCL3 in these cells
than in their MBP-specific counterparts [12]. This activation
stage may still provide enough surface expression of Ox40
to augment antigen-driven TCR-signaling, thus enabling
low doses of antigen to promote responses normally only
induced by higher doses [29]. Intermediately activated
S100β-specific T cells only produce low amounts of IFN-γ,
but may compensate for this by being present in the CNS
parenchyma in high cell numbers. This could explain
why S100β-specific T cells are still able to facilitate the
formation of astrocyte-destructive lesions in NMO-IgG
seropositive animals.
However, if T cells were not activated at all in the
CNS – as exemplified by MOG-specific T cells –, recruited
macrophages/activated microglial cells in extremely low
numbers, and did not compensate for low IFN-γ produc-
tion levels by high parenchymal cell numbers, astrocyte-
destructive lesions in the presence of NMO-IgG and
complement were not formed despite inflammation-
induced blood–brain barrier leakage.
Is there any evidence for the activation of AQP4-
specific T cells in NMO/EAE? This question could not
yet be experimentally addressed, since all AQP4-specific
rat T cells tested so far were only weakly encephalitogenic
[22] and could not be re-isolated in sufficiently high
numbers to test their surface expression of activation
markers by FACS analysis, and since commercially avail-
able antibodies against the rat Ox40 antigen did not work
in paraffin-embedded or frozen tissue. However, AQP4-
Figure 7 (See legend on next page.)
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Figure 7 Loss of AQP4 reactivity in NMO-like lesions initiated by T cells with different CNS antigen-specificities. (A-F) T cells specific for
MBP (A,B), S100β (C,D) and MOG (E,F) were used to induce CNS inflammation, followed by transfer of NMO-IgG 4 days later. The animals were
sacrificed 5 days after T cell transfer. For histological evaluation, their spinal cords were reacted with anti-AQP4 antibodies (brown reaction product)
and counterstained with hematoxylin to reveal nuclei (blue). bars = 500 μm (A,C,E) and 100 μm (B,D,F). (G) The average number of lesions with AQP4
loss per spinal cord cross section, as determined by evaluating 5 representative spinal cord cross sections (1 cervical, 2 thoracal, and 2 lumbar cross
sections) per animal, using 5 animals (MBP, MOG) and 4 animals (S100β) per group. Asterisks indicate statistically significant differences between individual
CNS antigen specificities of the T cells used to induce CNS inflammation (ANOVA-Holm Sidak; p < 0,001 for MBP-specific T cells compared to
MOG-specific T cells; p = 0,008 for MBP-specific T cells compared to S100β-specific T cells; and p = 0,005 for S100β-specific T cells compared to
MOG-specific T cells). (H) The largest lesion with AQP4 loss per animal, using 5 animals (MBP, MOG) and 4 animals (S100β) per group. Asterisks
indicate statistically significant differences between individual CNS antigen specificities of the T cells used to induce CNS inflammation
(Mann–Whitney U test with Bonferroni-Holm correction; p = 0,732 for MBP/S100β, p = 0,024 for MBP/MOG, p = 0,048 for S100β/MOG).
Figure 8 Differences in T cell activation translate into differences in IFN-γ production, which affects the microglial expression of
complement factors and complement inhibitors. (A) Normalized relative expression of IFN-γ mRNA in relation to the house-keeping gene beta
actin (calculated using the following equation: 2-ΔCt = 2-[Ct(GOI)-Ct(HKG)] (GOI – Gene of interest; HKG – house-keeping gene; [19]) are shown. Statistically
significant differences (*, as determined by one-way ANOVA followed by Bonferroni’s post-hoc testing) were observed between MBP-specific T cells
and their MOG- or S100β-specific counterparts. (B) Pathways contributing to the complement cascade [20] and alterations in gene expression (encircled
in red: upregulation; encircled in green: downregulation) of complement factors and inhibitors by IFN-γ treated microglia. (C-D) Changes in
gene expression of complement factors and inhibitors (C) and of Fcgr3 (D) in IFN-γ treated microglia. These cells were treated for 48 hrs with
100 ng/ml IFN-γ. Subsequently, the mRNA of these cells was harvested and subjected to gene expression profiling. Log2-fold changes in gene
expression and differences in the normalized signal intensities (nSI) of complement components/factors and Fcgr3 between IFN-γ and vehicle
control-treated microglial cultures are shown (2 different, independent samples per treatment group). Genes with elevated expression in the
IFN-γ treated group are labeled red, genes with lower expression levels are labeled green.
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http://www.actaneurocomms.org/content/1/1/85specific T cells cause lesions with AQP4 loss in NMO-IgG
seropositive hosts [22], which suggests an activation of
these cells within the CNS.
It might be argued that NMO is a TH17-driven disease
[30,31], while NMO/EAE is driven by TH1 T cells [5,21],
and that our findings about the consequences of activated,
IFN-γ producing cells might be irrelevant for NMO.
However, human TH17 cells comprise a heterogeneous
subset of cells including IFN-γ-producing cells [32-34]
and have the ability to shift to TH1 cells [35].
It was unexpected to see significantly higher numbers
of T-cells expressing the activation marker Ox40 in
active NMO compared to active MS lesions. Since this
was the case in early as well as late active lesions, and
in brain as well as spinal cord lesions, this observation
cannot simply be explained by stage or location dependent
differences in the lesions. In NMO lesions, Ox40 expres-
sion is seen in CD4+ T cells, and it has been described that
activated CD4+ T cells have prolonged Ox40 expression
[24]. In MS lesions, however, the activated T cells might
belong to the clonally expanded CD8+ T cell pool [36],
and Ox40 expression in activated CD8+ T cells appears to
be more transient compared to that in activated CD4+
T cells [24]. Hence, Ox40 expression in MS lesions may
escape detection.
Conclusion
In summary our data indicate that even in conditions of
inflammation and blood–brain barrier damage alone, entry
of AQP4 specific autoantibodies into the CNS is insuffi-
cient to trigger astrocyte destructive NMO lesions and that
the additional activation of effector mechanisms in the
lesions is necessary to facilitate complement-mediated
and antibody-dependent cellular cytotoxicity. Such an
environment is provided in T cell-mediated inflammation
when invading T cells are antigen-specifically activated
within the CNS. Our data further suggest that a similar
mechanism may operate in human NMO lesions, since
the infiltrating T-cells show the respective signs of activa-
tion. Whether these cells recognize AQP4 or other CNS
antigens is not resolved yet, since CD4+ T cells specific for
AQP4 [37,38] or PLP [37] have been observed in the
peripheral blood of NMO patients.
Additional file
Additional file 1: Figure S1. T cells with different CNS antigen-specificity
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the expression of T cell receptors (TCR), interleukin-2 receptors (IL-2R) or the
Ox40 antigen, using specific antibodies for these molecules and an isotype
control (IgG). MBP-specific T cells were strongly activated, as evidenced by a
down-regulation of TCR, and an up-regulation of IL-2R and the Ox40 antigen.S100β-specific T cells showed an intermediated degree of activation (i.e. no
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